Joshua A Bauer

Dr. Joshua A Bauer

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2014 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
BLBrian Lehmann
Brian Lehmann
JBJoshua A Bauer
Joshua A Bauer
JSJohanna M Schafer
Johanna M Schafer
CPChristopher S Pendleton
Christopher S Pendleton
LTLuojia Tang
Luojia Tang
JPJennifer A Pietenpol
Jennifer A Pietenpol
Introduction: Triple negative breast cancer (TNBC) is a heterogeneous collection of biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we identified a TNBC subtype that has a luminal phenotype and expresses the androgen receptor (AR+). TNBC cells derived from these luminal AR + tumors have high frequency phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. The purpose of this study was to determine if targeting phosphoinositide 3-kinase (PI3K) alone or in combination with an AR antagonist is effective in AR + TNBC. Methods: We determined the frequency of activating PIK3CA mutations in AR + and AR- TNBC clinical cases. Using AR + TNBC cell line and xenograft models we evaluated the effectiveness of PI3K inhibitors, used alone or in combination with an AR antagonist, on tumor cell growth and viability. Results: PIK3CA kinase mutations were highly clonal, more frequent in AR + vs. AR- TNBC (40% vs. 4%), and often associated with concurrent amplification of the PIK3CA locus. PI3K/mTOR inhibitors had an additive growth inhibitory effect when combined with genetic or pharmacological AR targeting in AR + TNBC cells. We also analyzed the combination of bicalutamide +/- the pan-PI3K inhibitor GDC-0941 or the dual PI3K/mTOR inhibitor GDC-0980 in xenograft tumor studies and observed additive effects. Conclusions: While approximately one third of TNBC patients respond to neoadjuvant/adjuvant chemotherapy, recent studies have shown that patients with AR + TNBC are far less likely to benefit from the current standard of care chemotherapy regimens and novel targeted approaches need to be investigated. In this study, we show that activating PIK3CA mutations are enriched in AR + TNBC; and, we show that the growth and viability of AR + TNBC cell line models is significantly reduced after treatment with PI3K inhibitors used in combination with an AR antagonist. These results provide rationale for pre-selection of TNBC patients with a biomarker (AR expression) to investigate the use of AR antagonists in combination with PI3K/mTOR inhibitors.

11 March 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
JSJohanna M. Schafer
Johanna M. Schafer
BLBrian Lehmann
Brian Lehmann
PGPaula I. Gonzalez-Ericsson
Paula I. Gonzalez-Ericsson
CMClayton B. Marshall
Clayton B. Marshall
JBJ. Scott Beeler
J. Scott Beeler
JPJennifer A. Pietenpol
Jennifer A. Pietenpol
This study demonstrates the potential utility of BET and MEK inhibitors for advanced MYCN-expressing triple-negative breast cancer.

14 November 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JMJonathan D. Macdonald
Jonathan D. Macdonald
SSSelena Chacón Simon
Selena Chacón Simon
Changho HanChangho Han
Changho Han
FWFeng Wang
Feng Wang
JSJ. Grace Shaw
J. Grace Shaw
SFStephen W. Fesik
Stephen W. Fesik

4 November 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Yan GuoYan Guo
Yan Guo
QSQuanhu Sheng
Quanhu Sheng
DSDavid C. Samuels
David C. Samuels
BLBrian Lehmann
Brian Lehmann
JBJoshua A Bauer
Joshua A Bauer
YSYu Shyr
Yu Shyr
Exome sequencing using next-generation sequencing technologies is a cost-efficient approach to selectively sequencing coding regions of the human genome for detection of disease variants. One of the lesser known yet important applications of exome sequencing data is to identify copy number variation (CNV). There have been many exome CNV tools developed over the last few years, but the performance and accuracy of these programs have not been thoroughly evaluated. In this study, we systematically compared four popular exome CNV tools (CoNIFER, cn.MOPS, exomeCopy, and ExomeDepth) and evaluated their effectiveness against array comparative genome hybridization (array CGH) platforms. We found that exome CNV tools are capable of identifying CNVs, but they can have problems such as high false positives, low sensitivity, and duplication bias when compared to array CGH platforms. While exome CNV tools do serve their purpose for data mining, careful evaluation and additional validation is highly recommended. Based on all these results, we recommend CoNIFER and cn.MOPs for nonpaired exome CNV detection over the other two tools due to a low false-positive rate, although none of the four exome CNV tools performed at an outstanding level when compared to array CGH.

3 January 2025 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GJGuochong Jia
Guochong Jia
ZCZhishan Chen
Zhishan Chen
JPJie Ping
Jie Ping
QCQiuyin Cai
Qiuyin Cai
RTRan Tao
Ran Tao
WZWei Zheng
Wei Zheng

17 December 2012 in BMC Genomics
Verified
Journal Article
Open access
FYFei Ye
Fei Ye
JBJoshua A Bauer
Joshua A Bauer
JPJennifer A Pietenpol
Jennifer A Pietenpol
YSYu Shyr
Yu Shyr
Background: High-throughput RNA interference (RNAi) screens have been used to find genes that, when silenced, result in sensitivity to certain chemotherapy drugs. Researchers therefore can further identify drug-sensitive targets and novel drug combinations that sensitize cancer cells to chemotherapeutic drugs. Considerable uncertainty exists about the efficiency and accuracy of statistical approaches used for RNAi hit selection in drug sensitivity studies. Researchers require statistical methods suitable for analyzing high-throughput RNAi screening data that will reduce false-positive and false-negative rates. Results: In this study, we carried out a simulation study to evaluate four types of statistical approaches (fold-change/ratio, parametric tests/statistics, sensitivity index, and linear models) with different scenarios of RNAi screenings for drug sensitivity studies. With the simulated datasets, the linear model resulted in significantly lower false-negative and false-positive rates. Based on the results of the simulation study, we then make recommendations of statistical analysis methods for high-throughput RNAi screening data in different scenarios. We assessed promising methods using real data from a loss-of-function RNAi screen to identify hits that modulate paclitaxel sensitivity in breast cancer cells. High-confidence hits with specific inhibitors were further analyzed for their ability to inhibit breast cancer cell growth. Our analysis identified a number of gene targets with inhibitors known to enhance paclitaxel sensitivity, suggesting other genes identified may merit further investigation. Conclusions: RNAi screening can identify druggable targets and novel drug combinations that can sensitize cancer cells to chemotherapeutic drugs. However, applying an inappropriate statistical method or model to the RNAi screening data will result in decreased power to detect the true hits and increase false positive and false negative rates, leading researchers to draw incorrect conclusions. In this paper, we make recommendations to enable more objective selection of statistical analysis methods for high-throughput RNAi screening data.